BCAR3 and breast neoplasm: In a cohort of patients with ER+ breast tumors treated with endocrine therapy for 5 years (NCBI GEO dataset GDS807) [34], those who developed disease relapse had lower levels of BCAR3 expression levels in their primary tumors as determined by log-transformed raw readings of the microarray dataset, which are expressed as relative fluorescence signaling intensities (Figure 1g).